RXi gets $300K SBIR grant for retinal cancer therapy

Mass High Tech: The Journal of New England Technology

Westborough-based RXi Pharmaceuticals Corporation (OTC: RXII) has been awarded a $300,000 Small Business Innovation Research (SBIR) grant by the National Cancer Institute (NCI) to develop therapeutic RNAi compounds that can be self-delivered to more effectively treat a retinal cancer commonly affecting children.